Champignon Brands Inc (CSE:SHRM) (OTCMKTS:SHRMF) announced Friday that it had received DTC eligibility to simplify the process of trading and transferring shares in the US.
The DTC, or Depository Trust Company, allows Champignon’s shares to be eligible for electronic clearing and settlement.
“We are actively engaged in pursuing new avenues of distribution both in North America and internationally, in order to enhance the ability of larger audiences to participate in the Champignon story, as well as broaden our already robust shareholder base,” said Gareth Birdsall, Champignon’s CEO.
READ: Champignon Brands inks blockbuster deal to roll out network of psychedelic medicine clinics in North America
“With the receipt of DTC eligibility, our common shares will become accessible to United States investors, both retail and institutional - the jurisdiction where many of the important initiatives in psychedelic medicine are emanating and where the company plans to roll out new clinical entities within significant urban population centres."
The Vancouver-based company is positioning itself as a leader in the burgeoning psychedelics space. It is planning to roll out five unique ketamine clinics across Florida, California and the US Eastern Seaboard, with additional ketamine clinics projected to be fully operational by the fourth quarter of 2020.
Contact Angela at [email protected]estors.com
Follow her on Twitter @AHarmantas